Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
Biogen Inc. stock outperforms competitors despite losses on the day
This was the stock's second consecutive day of losses.
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
GlobalData on MSN1d
Sanofi taps Alloy Therapeutics for CNS antisense drug development
As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
Biogen appoints Feire as Head of Business Development and External Innovation
Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...
Peering Into Biogen's Recent Short Interest
According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers. Did you know that ...
Biogen price target lowered to $220 from $302 at Truist
Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...
Hosted on MSN6d
Piper Sandler Downgrades Biogen (BIIB)
Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight to ...
STAT22h
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
Seeking Alpha7d
Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds
Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company's challenges in establishing its presence in the market for Alzheimer ...